Clinical Trial Update: Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial in triple-negative breast cancer compares regimens of SAR240550 with weekly paclitaxel versus paclitaxel alone.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• SAR240550

Snippet

Sponsor: Sanofi | Conditions: Breast Cancer Female | Phase 2 | Status: COMPLETED